Breast Cancer Core Needle Biopsy - Global Stategic Business Report

The global market for Breast Cancer Core Needle Biopsy was estimated at US$843.9 Million in 2024 and is projected to reach US$1.0 Billion by 2030, growing at a CAGR of 3.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Breast Cancer Core Needle Biopsy market.

Global Breast Cancer Core Needle Biopsy Market - Key Trends & Drivers Summarized

Why Is the Demand for Core Needle Biopsy Increasing?

Breast cancer core needle biopsy has emerged as the preferred diagnostic technique due to its minimally invasive nature and high diagnostic accuracy. With breast cancer being one of the leading causes of cancer-related deaths worldwide, early detection remains a critical factor in improving patient outcomes. Core needle biopsy offers a safer and more efficient alternative to surgical biopsies, reducing recovery time and procedural risks. The increasing global burden of breast cancer cases has driven the adoption of advanced biopsy techniques, with healthcare providers emphasizing early and precise diagnosis to ensure effective treatment planning. Additionally, the rising awareness about routine breast cancer screenings, along with government and private sector initiatives promoting diagnostic advancements, has significantly boosted the market demand for breast cancer core needle biopsy procedures.

What Technological Innovations Are Enhancing Biopsy Accuracy?

The market for breast cancer core needle biopsy is witnessing rapid technological advancements that are improving diagnostic precision and patient comfort. Innovations such as vacuum-assisted biopsy systems, real-time ultrasound guidance, and AI-powered image analysis are revolutionizing the biopsy process. These advanced technologies allow for precise tissue extraction, reducing the chances of false negatives and inconclusive results. Additionally, the integration of 3D imaging and digital pathology in biopsy procedures is enhancing the visualization of tumor characteristics, leading to improved detection of early-stage malignancies. As AI and machine learning applications continue to evolve, automated biopsy interpretation tools are further enhancing diagnostic accuracy, reducing variability in pathology reports, and expediting treatment decisions. The continued focus on technological improvements is expected to significantly impact the effectiveness of breast cancer diagnostics.

Which Healthcare Sectors Are Leading the Adoption of Core Needle Biopsy?

The adoption of core needle biopsy is being driven by multiple healthcare segments, including hospitals, diagnostic laboratories, and specialized breast cancer screening centers. Hospitals remain the primary providers of core needle biopsy procedures due to their advanced infrastructure and accessibility to state-of-the-art imaging and pathology services. Diagnostic laboratories are also experiencing increased demand for biopsy services as outpatient diagnostic testing becomes more prevalent. Moreover, mobile screening units and telemedicine platforms are expanding access to early-stage breast cancer diagnostics, particularly in rural and underserved areas. Private healthcare providers and cancer research institutions are also investing heavily in innovative biopsy techniques, ensuring that patients receive accurate and timely diagnoses. With the integration of digital health solutions and remote diagnostic capabilities, the market for breast cancer core needle biopsy is set to expand further.

What Factors Are Driving Market Growth?

The growth in the breast cancer core needle biopsy market is driven by several factors, including rising breast cancer incidence rates, advancements in biopsy technologies, and increasing awareness about early cancer detection. The shift towards minimally invasive procedures has fueled the adoption of core needle biopsy over traditional surgical biopsies, as it offers quicker recovery and reduced patient discomfort. Government-backed screening programs and healthcare reimbursement policies have also contributed to market expansion by making diagnostic procedures more accessible. Additionally, the increasing investment in AI-driven biopsy analysis tools and precision diagnostics is transforming the biopsy landscape, improving detection rates, and streamlining workflow efficiencies. As the demand for high-precision breast cancer diagnostics continues to rise, the breast cancer core needle biopsy market is expected to witness sustained growth in the coming years.

Report Scope

The report analyzes the Breast Cancer Core Needle Biopsy market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Technology (Ultrasound-based Breast Biopsy, MRI-based Breast Biopsy, Mammography-based (Stereotactic) Breast Biopsy, CT-based Breast Biopsy, Other Technologies); End-Use (Hospitals and Diagnostic Laboratories End-Use, Pharmaceutical and Biotechnology Companies End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Ultrasound-based Breast Biopsy segment, which is expected to reach US$569.3 Million by 2030 with a CAGR of a 4.0%. The MRI-based Breast Biopsy segment is also set to grow at 3.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $229.9 Million in 2024, and China, forecasted to grow at an impressive 6.5% CAGR to reach $206.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Breast Cancer Core Needle Biopsy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Breast Cancer Core Needle Biopsy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Breast Cancer Core Needle Biopsy Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Argon Medical Devices, Inc., Becton, Dickinson and Company (BD), Boston Scientific Corporation, C.R. Bard, Inc. (BD), Cardinal Health, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 42 Featured):

• Argon Medical Devices, Inc.
• Becton, Dickinson and Company (BD)
• Boston Scientific Corporation
• C.R. Bard, Inc. (BD)
• Cardinal Health, Inc.
• Cook Medical Incorporated
• Danaher Corporation (Leica Biosystems)
• Devicor Medical Products, Inc. (acquired by Leica Biosystems)
• Encapsule Medical Devices LLC
• Ethicon Endo-Surgery, Inc. (a Johnson & Johnson company)
• Fujifilm Holdings Corporation
• Gallini S.r.l.
• Hologic, Inc.
• Intact Medical Corporation
• Leica Biosystems Nussloch GmbH
• Mammotome (a division of Devicor Medical Products, Inc.)
• Medtronic plc
• Olympus Corporation
• SenoRx, Inc. (acquired by C.R. Bard)
• Stryker Corporation

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry